Ivabradine in heart failure-no paradigm SHIFT⋯yet

The Lancet

Volumn 376, Issue 9744, 2010, Pages 847-849

  Teerlink, John R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; IVABRADINE;

AGED; DRUG EFFECTS; FEMALE; HEART FAILURE, SYSTOLIC; HEART RATE; HEART STROKE VOLUME; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; BENZAZEPINES; CARDIOVASCULAR AGENTS; FEMALE; HEART FAILURE, SYSTOLIC; HEART RATE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; TREATMENT OUTCOME;

EID: 77956617171     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61314-1     Document Type: Note

References (19)

1. K Swedberg, M Komajda, M Böhm on behalf of the SHIFT Investigators Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 2010 10.1016/S01406736(10)61198-1 published online Aug 29.
2. M Böhm, K Swedberg, M Komajda on behalf of the SHIFT Investigators Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial Lancet 2010 10.1016/S0140-6736(10)61259-7 published online Aug 29.
3. H Brown, D Difrancesco, S Noble Cardiac pacemaker oscillation and its modulation by autonomic transmitters J Exp Biol 81 1979 175 204
4. D DiFrancesco The role of the funny current in pacemaker activity Circ Res 106 2010 434 446
5. K Swedberg Fallacies in clinical cardiovascular trials Heart 95 2009 1464 1468
6. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 353 1999 2001 2007
7. CIBIS Investigators and Committees A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS) Circulation 90 1994 1765 1773
8. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial Lancet 353 1999 9 13
9. Australia/New Zealand Heart Failure Research Collaborative Group Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease Lancet 349 1997 375 380
10. M Packer, MR Bristow, JN Cohn for the U.S. Carvedilol Heart Failure Study Group The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group N Engl J Med 334 1996 1349 1355
11. M Packer, AJ Coats, MB Fowler for the Carvedilol Prospective Randomized Cumulative Survival Study Group Effect of carvedilol on survival in severe chronic heart failure N Engl J Med 344 2001 1651 1658 (Pubitemid 32479962)
12. PA Poole-Wilson, K Swedberg, JG Cleland for the COMET investigators Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 2003 7 13
13. K Fox, I Ford, PG Steg, M Tendera, R Ferrari on behalf of the BEAUTIFUL Investigators Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 807 816
14. E Cerbai, L Sartiani, P DePaoli The properties of the pacemaker current I(F)in human ventricular myocytes are modulated by cardiac disease J Mol Cell Cardiol 33 2001 441 448
15. G Michels, MC Brandt, N Zagidullin Direct evidence for calcium conductance of hyperpolarization-activated cyclic nucleotide-gated channels and human native If at physiological calcium concentrations Cardiovasc Res 78 2008 466 475
16. G Heusch, A Skyschally, P Gres, P van Caster, D Schilawa, R Schulz Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction Eur Heart J 29 2008 2265 2275
17. F Custodis, M Baumhakel, N Schlimmer Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice Circulation 117 2008 2377 2387
18. A Drouin, ME Gendron, E Thorin, MA Gillis, F Mahlberg-Gaudin, JC Tardif Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice Br J Pharmacol 154 2008 749 757
19. P Palatini Elevated heart rate in cardiovascular diseases: a target for treatment? Prog Cardiovasc Dis 52 2009 46 60